The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability

In the search for drugs to effectively treat cancer, the last 10 years have seen a resurgence of interest in targeting ribosome biogenesis. CX-5461 is a potential inhibitor of ribosomal RNA synthesis that is now showing promise in phase I trials as a chemotherapeutic agent for a range of malignancie...

Descripción completa

Detalles Bibliográficos
Autores principales: Mars, Jean-Clément, Tremblay, Michel G, Valere, Mélissa, Sibai, Dany S, Sabourin-Felix, Marianne, Lessard, Frédéric, Moss, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Nucleic Acid-Based Cancer Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646227/
https://www.ncbi.nlm.nih.gov/pubmed/33196044
http://dx.doi.org/10.1093/narcan/zcaa032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646227/
https://www.ncbi.nlm.nih.gov/pubmed/33196044
http://dx.doi.org/10.1093/narcan/zcaa032

Ejemplares similares